Genetic polymorphism and response to treatment in chronic hepatitis C: The future of personalized medicine

Journal of Hepatology

Volumn 52, Issue 3, 2010, Pages 452-454

  Asselah, Tarik ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON 3; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ARTICLE; CAUSE OF DEATH; DRUG EFFICACY; DRUG TOLERABILITY; EUROPEAN UNION; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; IL28B GENE; MORTALITY; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; TREATMENT RESPONSE;

EID: 77249087581     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.11.016     Document Type: Note

References (10)

1. Asselah T., Bieche I., Sabbagh A., Bedossa P., Moreau R., Valla D., et al. Gene expression and hepatitis C virus infection. Gut 58 (2009) 846-858
2. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 (2009) 399-401
3. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41 (2009) 1100-1104
4. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41 (2009) 1105-1109
5. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., et al. Genetic variation in IL28B and to spontaneous clearance of hepatitis C virus. Nature 461 (2009) 798-801
6. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4 (2003) 63-68
7. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E.S., Kotenko S.V., MacDonald M.R., et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131 (2006) 1887-1898
8. Asselah T., Bieche I., Narguet S., Sabbagh A., Laurendeau I., Ripault M.P., et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57 (2008) 516-524
9. Asselah T., Benhamou Y., and Marcellin P. Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int 29 (2009) 57-67
10. Foy E., Li K., Wang C., Sumpter Jr. R., Ikeda M., Lemon S.M., et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300 (2003) 1145-1148